WO2006038613A1 - Oral composition containing difructose anhydride - Google Patents
Oral composition containing difructose anhydride Download PDFInfo
- Publication number
- WO2006038613A1 WO2006038613A1 PCT/JP2005/018346 JP2005018346W WO2006038613A1 WO 2006038613 A1 WO2006038613 A1 WO 2006038613A1 JP 2005018346 W JP2005018346 W JP 2005018346W WO 2006038613 A1 WO2006038613 A1 WO 2006038613A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium
- potassium
- excretion
- dfa
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 150000008064 anhydrides Chemical class 0.000 title claims abstract description 14
- 239000011591 potassium Substances 0.000 claims abstract description 49
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 49
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 48
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 47
- 239000011734 sodium Substances 0.000 claims abstract description 47
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 47
- 230000029142 excretion Effects 0.000 claims abstract description 37
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 230000001737 promoting effect Effects 0.000 claims abstract description 16
- 230000000694 effects Effects 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims description 13
- 230000002411 adverse Effects 0.000 claims description 6
- 239000003623 enhancer Substances 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims 2
- 230000035622 drinking Effects 0.000 claims 1
- 230000009931 harmful effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 235000005911 diet Nutrition 0.000 abstract description 5
- 230000037213 diet Effects 0.000 abstract description 4
- 230000003449 preventive effect Effects 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 4
- 239000011780 sodium chloride Substances 0.000 abstract 2
- 208000019423 liver disease Diseases 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000015598 salt intake Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000185 sucrose group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000186073 Arthrobacter sp. Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 description 1
- -1 acidulants Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 238000012851 eutrophication Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021127 solid diet Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an oral composition having a function of promoting sodium and Z or potassium excretion.
- the present invention also relates to an oral composition that has a function of promoting sodium excretion, thereby preventing or ameliorating a disease caused by excessive intake of salt.
- the present invention also relates to an oral composition intended to be useful for restricting sodium and / or potassium intake in patients with kidney disease by having a function of promoting sodium and / or potassium excretion.
- Patent Document 1 discloses a component having a function of excreting dietary sodium mainly composed of polysaccharides outside the body. ing.
- DFA difructose anhydride
- Patent Document 1 JP 2002-87980 A
- Patent Document 2 Japanese Patent Laid-Open No. 2000-270811
- Patent Document 3 Japanese Patent Publication No. 3-5788
- Patent Document 4 Japanese Patent Laid-Open No. 11-43438
- Patent Document 5 Japanese Unexamined Patent Application Publication No. 2003-321371
- Excessive intake of salt is considered to be one of the causes of diseases related to lifestyle-related diseases and their complications, and exacerbations.
- a new composition that improves the adverse effects of excessive intake of salt and prevention improvement The purpose is to provide drugs, food and drink, and feed.
- the present inventors paid attention to the action of promoting sodium excretion via the intestinal tract, and, as a result of continuing research, have the function of promoting excretion of sodium in the body via the intestinal tract. It was found that sodium excretion is promoted via the intestinal tract by the administration of DFA, which has a preventive and ameliorating effect on diseases caused by excessive intake of. Furthermore, the present inventors have paid attention to the effect of promoting potassium excretion via the intestine, and as a result of continuing research, as a result of administration of DFA having a function of promoting potassium excretion via the intestine, It was found that excretion of physical strength rhodium is promoted. That is, the present invention focuses on the function of DFA as an active ingredient that promotes excretion of sodium and Z or potassium in the intestinal tract.
- the main configuration of the present invention that makes use of this function is as follows.
- An oral composition for promoting sodium and Z or potassium excretion characterized by containing difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium
- An oral composition for improving sodium and Z or potassium overdose prevention characterized by containing difructose anhydride (DFA) as a fraction.
- DFA difructose anhydride
- a sodium, Z or potassium excretion enhancer comprising difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium.
- DFA difructose anhydride
- DFA difructose anhydride
- DFA difructose anhydride
- a pet feed characterized by containing difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium.
- DFA difructose anhydride
- DFA difructose anhydride
- the oral composition containing DFA of the present invention promotes in vivo sodium excretion or in vivo potassium excretion via the intestinal tract.
- the DFA referred to in the present invention is an anhydrocyclic disaccharide bonded to two fractoskas at two points.
- Traditionally known to exist in caramel etc. Is produced by fermenting inulin with an inulin-degrading enzyme such as inulin flatrate transferase (EC2.4.1.93) produced by Arthrobacter sp. It can be produced by fermenting with an fructotransferase (EC 2.4.1. 10).
- DFAI DFAIU DFAIII, DFAIV, and DFAV, respectively.
- DFA refers to all of them.
- DFAII I m-D-fructofuranose- ⁇ , 2 ': 2,3 dianhyaride
- DFAIV di-D-fructofuranose-2, 6,2' dianhydride
- the oral composition according to the present invention contains DFA as an active ingredient and can be used as a composition of a pharmaceutical type, a food and drink type, a pet animal feed type, for example, a human or There are no limitations as long as it is a form that can be finally administered orally, such as pharmaceuticals for pet animals, foods and drinks, formula milk, enteral nutrition, health foods and drinks, and pet food additives. Moreover, the content of the active ingredient is not particularly limited.
- DFA or a processed product thereof can be used as it is or in combination with other foods or food ingredients, and can be used according to conventional methods.
- heat stability and acid stability are high, ordinary food processing methods can be applied without any problems.
- Food-type oral compositions containing DFA are not subject to any particular limitation such as powder, granule, paste, liquid or suspension.
- it can be formulated into a health drink using various ingredients commonly used in the manufacture of sweeteners, acidulants, vitamins and other drinks.
- the active ingredient When used as a pharmaceutical type composition, the active ingredient is administered in various forms.
- Examples of the dosage form include oral administration using tablets, capsules, granules, powders, syrups and the like. These various preparations are usually used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizing agents, suspension agents, coating agents, etc. as main ingredients in accordance with conventional methods. Can be formulated with known adjuvants wear. The amount used varies depending on symptoms, age, body weight, and dosage form, but is usually 0.5 to 2000 mg / kg body weight per day when administered orally, preferably 1 to 1 for adults.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
- Feed For Specific Animals (AREA)
Abstract
It is considered that the excessive intake of sodium chloride is one of factors causative of the onset and worsening of diseases classified into life-style-related diseases and complications thereof. Thus, it is intended to provide a novel composition for lessening undesirable effects of the excessive intake of sodium chloride as well as preventives, remedies, foods, drinks and pet feeds therefor. It is also intended to elevate the degree of freedom in the diet of patients suffering from liver disorders by promoting the excretion of sodium and/or potassium. Namely, an oral composition for promoting the excretion of sodium and/or potassium which contains difructose anhydride (DFA) as the active ingredient for promoting the excretion of sodium and/or potassium.
Description
明 細 書 Specification
ダイフラクトース アンハイドライド含有経口組成物 Oral composition containing difructose anhydride
技術分野 Technical field
[oooi] 本発明は、ナトリウム及び Z又はカリウム排泄促進機能をもつ経口組成物に関する ものである。また、ナトリウム排泄促進機能をもつことにより、食塩過剰摂取に起因す る疾患の予防及び改善作用をもつ経口組成物に関するものである。また、ナトリウム 及び/又はカリウム排泄促進機能をもつことにより、腎臓病患者のナトリウム及び/又 はカリウム摂取制限に対して役立つ事を目的とした経口組成物に関するものである。 背景技術 [oooi] The present invention relates to an oral composition having a function of promoting sodium and Z or potassium excretion. The present invention also relates to an oral composition that has a function of promoting sodium excretion, thereby preventing or ameliorating a disease caused by excessive intake of salt. The present invention also relates to an oral composition intended to be useful for restricting sodium and / or potassium intake in patients with kidney disease by having a function of promoting sodium and / or potassium excretion. Background art
[0002] 国民栄養調査によると、日本人の食塩摂取目安量である 10gに対し、過剰に摂取し ている。食塩の過剰摂取は高血圧、ひいてはそれに伴う合併症の発生につながり、 深刻な問題である。このような現状に対し、主に多糖類を主とした食事由来のナトリウ ムを体外に排泄する機能をもつ成分が特許文献 1 (W099/33478,特開 2002— 8798 0号公報）に知られている。 [0002] According to the National Nutrition Survey, the Japanese intake of excessive salt is 10g, which is the standard amount of salt intake in Japan. Excessive salt intake is a serious problem, leading to the development of hypertension and thus complications. In response to this situation, Patent Document 1 (W099 / 33478, Japanese Patent Laid-Open No. 2002-87980) discloses a component having a function of excreting dietary sodium mainly composed of polysaccharides outside the body. ing.
[0003] また、カリウム排泄の調節は、腎臓の働きと、副腎皮質ホルモンの作用が密接に関 連して行われるが、腎臓や副腎の機能のわるい人では、カリウムの排泄がうまくいか ず、過剰にカリウムを摂取した場合 '高カリウム血症 (血漿中のカリウム濃度が上昇し、 心臓症状がみられてくる)をおこす危険がある。腎臓病患者における食事コントロール の課題の一つとして、カリウムの摂取制限があり、調理の煩雑さや、食事の不味さが 腎臓病者の QOL (Qualtiy of Life)を低下させている。このような現状に対し、様々な 低カリウム食品や、クェン酸を主成分としてその他成分を含む事でカリウムイオンの吸 収を抑制する事を目的とした食品 (特許文献 2 :特開 2000— 270811号公報)が開発さ れている。 [0003] In addition, the regulation of potassium excretion is closely related to the action of the kidney and the action of adrenal cortex hormones, but potassium excretion is poor in people with poor kidney and adrenal function. Excessive potassium intake may cause 'hyperkalemia (increased plasma potassium concentration and heart symptoms). One of the challenges of diet control in patients with kidney disease is the restriction of potassium intake, and the complexity of cooking and the unpleasantness of the meals lower the quality of life (QOL) of those with kidney disease. In response to this situation, various low-potassium foods and foods intended to suppress the absorption of potassium ions by containing other components with citrate as the main component (Patent Document 2: JP 2000-270811 A) No.) has been developed.
[0004] 本発明者等は、ダイフラクトースアンノヽイドライド (以下 DFAと記す）につ 、て、その 機能、応用について鋭意研究してきた。 DFAの機能としてはビフィズス菌増殖作用 を有すること (特許文献 3：特公平 3— 5788号公報)やカルシウム吸収量を増やすこ と (特許文献 4：特開平 11 43438号公報)、利尿作用をもつこと (特許文献 5：特開
2003— 321371号公報）が公知となっている。し力し、 DFAがナトリウム及び Z又は カリウムを腸管を経由して排泄促進させる機能をもつ事は知られていない。 [0004] The present inventors have diligently researched on the function and application of difructose anhydride (hereinafter referred to as DFA). The function of DFA has a bifidobacteria growth action (Patent Document 3: Japanese Patent Publication No. 3-5788), an increase in calcium absorption (Patent Document 4: Japanese Patent Laid-Open No. 11 43438), and a diuretic action. (Patent Document 5: JP 2003-321371) is publicly known. However, it is not known that DFA has the function of promoting excretion of sodium and Z or potassium via the intestinal tract.
[0005] 特許文献 1：特開 2002— 87980号公報 [0005] Patent Document 1: JP 2002-87980 A
特許文献 2：特開 2000 -270811号公報 Patent Document 2: Japanese Patent Laid-Open No. 2000-270811
特許文献 3：特公平 3— 5788号公報 Patent Document 3: Japanese Patent Publication No. 3-5788
特許文献 4：特開平 11—43438号公報 Patent Document 4: Japanese Patent Laid-Open No. 11-43438
特許文献 5 :特開 2003— 321371号公報 Patent Document 5: Japanese Unexamined Patent Application Publication No. 2003-321371
発明の開示 Disclosure of the invention
発明が解決しょうとする課題 Problems to be solved by the invention
[0006] 食塩の過剰摂取は生活習慣病に類される疾患、及びその合併症の発症、増悪の 原因の一つとされており、食塩の過剰摂取の悪影響を改善する新たな組成物、予防 改善剤、飲食品、飼料を提供することを目的とする。 [0006] Excessive intake of salt is considered to be one of the causes of diseases related to lifestyle-related diseases and their complications, and exacerbations. A new composition that improves the adverse effects of excessive intake of salt and prevention improvement The purpose is to provide drugs, food and drink, and feed.
また、ナトリウム及び Z又はカリウムの排泄を促進させることにより、腎臓に障害を抱 えて 、る者の食事の自由度を向上することを目的とする。 In addition, it aims to improve the degree of freedom of food for those who have a kidney disorder by promoting the excretion of sodium and Z or potassium.
課題を解決するための手段 Means for solving the problem
[0007] 本発明者らは、腸管を経由してナトリウム排泄を促進させる作用に注目し、研究を 続けた結果、腸管を経由して体内ナトリウムの排泄を促進する機能をもち、さらに、食 塩の過剰摂取に起因する疾患の予防、改善作用を有する DFAの投与によって腸管 を経由してナトリウム排泄が促進される事を見出した。さらに、本発明者らは、腸管を 経由してカリウム排泄を促進させる作用に注目し、研究を続けた結果、腸管を経由し てカリウム排泄を促進する機能をもつ DFAの投与によって腸管を経由して体内力リウ ムの排泄が促進される事を見出した。すなわち本発明は DFAが腸管内のナトリウム 及び Z又はカリウムを排泄促進させる有効成分としての機能に着目した発明である。 その機能を活力した本発明の主な構成は次のとおりである。 [0007] The present inventors paid attention to the action of promoting sodium excretion via the intestinal tract, and, as a result of continuing research, have the function of promoting excretion of sodium in the body via the intestinal tract. It was found that sodium excretion is promoted via the intestinal tract by the administration of DFA, which has a preventive and ameliorating effect on diseases caused by excessive intake of. Furthermore, the present inventors have paid attention to the effect of promoting potassium excretion via the intestine, and as a result of continuing research, as a result of administration of DFA having a function of promoting potassium excretion via the intestine, It was found that excretion of physical strength rhodium is promoted. That is, the present invention focuses on the function of DFA as an active ingredient that promotes excretion of sodium and Z or potassium in the intestinal tract. The main configuration of the present invention that makes use of this function is as follows.
(1)ナトリウム及び Z又はカリウムを排泄促進させる有効成分として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とするナトリウム及び Z又はカリウム排 泄促進用経口組成物 (1) An oral composition for promoting sodium and Z or potassium excretion, characterized by containing difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium
(2)ナトリウム及び Z又はカリウム過剰摂取による有害作用を予防、改善する有効成
分として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とするナトリ ゥム及び Z又はカリウム過剰摂取予防'改善用経口組成物。 (2) Effective prevention and prevention of adverse effects caused by excessive intake of sodium and Z or potassium An oral composition for improving sodium and Z or potassium overdose prevention, characterized by containing difructose anhydride (DFA) as a fraction.
(3)ナトリウム及び Z又はカリウムを排泄促進させる有効成分として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とするナトリウム及び Z又はカリウム排 泄促進剤。 (3) A sodium, Z or potassium excretion enhancer comprising difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium.
(4)ナトリウム及び Z又はカリウムを排泄促進させる有効成分として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とする飲食品。 (4) A food or drink comprising difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium.
(5)ナトリウム及び Z又はカリウム過剰摂取による有害作用を予防、改善する有効成 分として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とするナトリ ゥム及び Z又はカリウム過剰摂取予防，改善用飲食品。 (5) Prevention and improvement of sodium and Z or potassium overdose characterized by containing difructose anhydride (DFA) as an effective component to prevent and ameliorate adverse effects due to sodium and Z or potassium overdose Food and drink.
(6)ナトリウム及び Z又はカリウムを排泄促進させる有効成分として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とするペット飼料。 (6) A pet feed characterized by containing difructose anhydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium.
(7)ナトリウム及び Z又はカリウム過剰摂取による有害作用を予防、改善する有効成 分として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とするナトリ ゥム及び Z又はカリウム過剰摂取予防'改善用ペット飼料。 (7) Prevention of sodium and Z or potassium overdose prevention, characterized by containing difructose anhydride (DFA) as an effective component to prevent and ameliorate the adverse effects of sodium and Z or potassium overdose For pet feed.
発明の効果 The invention's effect
[0008] 本発明の DFAを含有する経口組成物は腸管を経由して生体内ナトリウム排泄ある いは生体内カリウム排泄を促進する。 [0008] The oral composition containing DFA of the present invention promotes in vivo sodium excretion or in vivo potassium excretion via the intestinal tract.
ナトリウム排泄を促進する事により、食塩の過剰摂取に起因する疾患の予防及び改 善作用を示す。また、腎臓病患者のナトリウム及び Z又はカリウム摂取制限に伴う QO Lの低下を改善する。 It promotes sodium excretion, thereby preventing and improving diseases caused by excessive salt intake. It also improves the QOL drop associated with restriction of sodium and Z or potassium intake in patients with kidney disease.
飲食品、ペット動物用飼料としても提供できる。 It can also be provided as food and drink and pet animal feed.
図面の簡単な説明 Brief Description of Drawings
[0009] [図 1]DFAIIIによる糞中へのナトリウム排泄促進を示すグラフ [0009] [Fig.1] Graph showing promotion of sodium excretion into feces by DFAIII
[図 2]DFAIIIによる糞中へのカリウム排泄促進を示すグラフ [Fig. 2] Graph showing the promotion of potassium excretion into feces by DFAIII
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0010] 本発明でいう DFAとは、 2個のフラクトースカ 互いに 2点ずつで結合したアンヒドロ 化環状二糖である。従来、カラメルなどに存在することが知られていた力 工業的に
は、ィヌリンをィヌリン分解酵素、例えば、 Arthrobacter sp.H65— 7株が産生するィヌ リンフラタトトランスフェラーゼ（EC2.4.1.93)により発酵させたり、レヴアンを Arthroba cter nicotinovorans GS— 9が産生するレヴアンフルクトトランスフェラーゼ（EC2.4.1. 10)により発酵させたりすることにより製造することができる。二分子のフラクトースの 結合様式の差異により、誘導体が 5種類存在し、それぞれ、 DFAI、 DFAIU DFAIII 、 DFAIV、 DFAVと称される。本発明でいう DFAとは、それら全てをいうが、本発明 では、もっぱら、工業的生産の効率、精製して力もの安定性などが優れている DFAII I (m- D- fructofuranose-丄, 2' ： 2,3 dianhyaride)、 DFAIV (di- D- fructofuranose- 2,り ： 6,2' dianhydride)が好ましく使用される。 [0010] The DFA referred to in the present invention is an anhydrocyclic disaccharide bonded to two fractoskas at two points. Traditionally known to exist in caramel etc. Is produced by fermenting inulin with an inulin-degrading enzyme such as inulin flatrate transferase (EC2.4.1.93) produced by Arthrobacter sp. It can be produced by fermenting with an fructotransferase (EC 2.4.1. 10). There are five types of derivatives due to the difference in the binding mode of bimolecular fructose, which are called DFAI, DFAIU DFAIII, DFAIV, and DFAV, respectively. In the present invention, DFA refers to all of them. In the present invention, DFAII I (m-D-fructofuranose- 丄, 2 ': 2,3 dianhyaride) and DFAIV (di-D-fructofuranose-2, 6,2' dianhydride) are preferably used.
本発明に係る経口組成物は、 DFAを有効成分として含有するものであって、医薬 品タイプ、飲食品タイプ、ペット動物用飼餌料タイプの組成物として利用することがで き、例えば、ヒト又はペット動物用の医薬品、飲食品、調製粉乳、経腸栄養剤、健康 飲食品、ペット飼餌料添加物など、最終的に経口投与可能な形態であれば制限はな い。また、有効成分の含有量は、特に限定されない。 The oral composition according to the present invention contains DFA as an active ingredient and can be used as a composition of a pharmaceutical type, a food and drink type, a pet animal feed type, for example, a human or There are no limitations as long as it is a form that can be finally administered orally, such as pharmaceuticals for pet animals, foods and drinks, formula milk, enteral nutrition, health foods and drinks, and pet food additives. Moreover, the content of the active ingredient is not particularly limited.
[0011] 飲食品タイプの組成物として使用する場合には、 DFA又はその処理物をそのまま 使用したり、他の食品ないし食品成分と併用したりして、適宜常法に従い使用できる 。また、力!]ェにあたっては、熱安定性、酸安定性が高いため、通常の食品加工方法 がなんら問題なく適用できる。 DFAを含有する食品タイプの経口組成物は、粉末、 顆粒状、ペースト状、液状、懸濁状など特段の限定は受けない。例えば甘味料、酸 味料、ビタミン剤その他ドリンク剤製造に常用される各種成分を用いて、健康ドリンク に製剤化することも例示できる。 [0011] When used as a food-and-beverage-type composition, DFA or a processed product thereof can be used as it is or in combination with other foods or food ingredients, and can be used according to conventional methods. In addition, since the heat stability and acid stability are high, ordinary food processing methods can be applied without any problems. Food-type oral compositions containing DFA are not subject to any particular limitation such as powder, granule, paste, liquid or suspension. For example, it can be formulated into a health drink using various ingredients commonly used in the manufacture of sweeteners, acidulants, vitamins and other drinks.
予防や改善用としても摂取することができる。 It can be taken for prevention or improvement.
[0012] 医薬品タイプの組成物として使用する場合、本有効成分は、種々の形態で投与さ れる。 [0012] When used as a pharmaceutical type composition, the active ingredient is administered in various forms.
その投与形態としては、例えば、錠剤、カプセル剤、顆粒剤、散剤、シロップ剤等によ る経口投与が例示できる。これらの各種製剤は、常法に従って主薬に賦形剤、結合 剤、崩壊剤、滑沢剤、矯味矯臭剤、溶解補助剤、懸濁剤、コーティング剤などの医薬 の製剤技術分野において通常使用しうる既知の補助剤を用いて製剤化することがで
きる。その使用量は症状、年令、体重、剤形によって異なるが、通常は、成人に対し て、経口投与の場合に 1日当たり、体重 lkg当たり 0. 5〜2000mg、好ましくは 1〜1Examples of the dosage form include oral administration using tablets, capsules, granules, powders, syrups and the like. These various preparations are usually used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizing agents, suspension agents, coating agents, etc. as main ingredients in accordance with conventional methods. Can be formulated with known adjuvants wear. The amount used varies depending on symptoms, age, body weight, and dosage form, but is usually 0.5 to 2000 mg / kg body weight per day when administered orally, preferably 1 to 1 for adults.
OOOmgの範囲で投与するのがよ!/、。 It should be administered in the range of OOOmg! /.
予防や改善用としても摂取することができる。 It can be taken for prevention or improvement.
[0013] ペット動物も富栄養化あるいは人と同様の食物をとる機会が増えるので、ペット動物 用剤あるいはペット飼料に添加してナトリウム及び Z又はカリウム排出を促進すること が有用である。また、予防や改善用としても摂取することができる。 [0013] Since pet animals also have an increased chance of eutrophication or eating foods similar to humans, it is useful to add sodium and Z or potassium excretion by adding them to pet animal preparations or pet feed. It can also be taken for prevention or improvement.
[0014] 〔実施例〕 [0014] [Example]
以下の実施例をもって本発明をより詳細に説明するが、これらは単に例示するのみ であり、本発明はこれらによって何ら限定されるものではない。 The present invention will be described in more detail with reference to the following examples, which are merely illustrative and the present invention is not limited thereto.
実施例 1 Example 1
[0015] DFAの腸管経由ナトリウム排泄促進機能を調べた。 [0015] The function of DFA to promote sodium excretion via the intestinal tract was examined.
Wistar系雄ラット (3週齢) 24匹を 3日間固形飼料で予備飼育した後、基本食 7g (ナト リウム 14mg含有)を 3日間与え、 3群に分けた。それぞれに基本食 7gのみ、基本食に DFAIII1. Og又はショ糖 1. Ogずつ足した飼料を与えた。 3週間の本飼育中、最後の 7日間の糞を採取し、凍結乾燥処理を行ったのち、乾燥糞中のナトリウム濃度を原子 吸光測定し、調べた。 After 24 Wistar male rats (3 weeks old) were preliminarily raised on solid feed for 3 days, they were given a basic diet of 7 g (containing 14 mg of sodium) for 3 days and divided into 3 groups. Only 7g of basic food was given to each, and the basic food was supplemented with DFAIII1.Og or 1.Og of sucrose. During the last 3 weeks of breeding, feces from the last 7 days were collected and freeze-dried, and then the sodium concentration in the dried feces was measured by atomic absorption measurement.
結果を図 1に示す。 The results are shown in Figure 1.
この結果から明らかなように、 DFAの摂取により、糞便中ナトリウム濃度の上昇が認 められた。また、各群の乾燥糞重量は基本食群 (4.3±0.1g)、ショ糖群 (4.3±0.2g)、 DFAIII群（4.8±0.1g)であった。 As is clear from this result, an increase in fecal sodium concentration was observed with DFA intake. The dry feces weight of each group was the basic food group (4.3 ± 0.1 g), sucrose group (4.3 ± 0.2 g), and DFAIII group (4.8 ± 0.1 g).
実施例 2 Example 2
[0016] DFAの腸管経由カリウム排泄促進機能を調べた。 [0016] The function of DFA to promote potassium excretion via the intestinal tract was examined.
Wistar系雄ラット (3週齢) 24匹を 3日間固形飼料で予備飼育した後、基本食 7g (カリ ゥム 50.4mg含有)を 3日間与え、 3群に分けた。それぞれに基本食 7gのみ、基本食に DFAIII 1. Og、ショ糖 1. Ogずつ足した飼料を与えた。 3週間の本飼育中、最後の 7 日間の糞を採取し、凍結乾燥処理を行ったのち、乾燥糞中のカリウム濃度を原子吸 光測定し、調べた。
結果を図 2に示す。 After 24 Wistar male rats (3 weeks old) were preliminarily raised on a solid diet for 3 days, they were given a basic diet of 7 g (containing 50.4 mg of potassium) for 3 days and divided into 3 groups. Only 7g of basic food was given to each, and the basic food was supplemented with DFAIII 1. Og and sucrose 1. Og. During the last 3 weeks of breeding, feces from the last 7 days were collected and freeze-dried, and the potassium concentration in the dried feces was measured by atomic absorption measurement. The result is shown in figure 2.
この結果から明らかなように、 DFAの摂取により、糞便中カリウム濃度の上昇が認 められた。また、各群の乾燥糞重量は基本食群 (4.3±0.1g)、ショ糖群 (4.3±0.2g)、 DFAIII群（4.8±0.1g)であった。 As is clear from this result, an increase in fecal potassium concentration was observed with DFA intake. The dry feces weight of each group was the basic food group (4.3 ± 0.1 g), sucrose group (4.3 ± 0.2 g), and DFAIII group (4.8 ± 0.1 g).
実施例 3 Example 3
DFAIIIを含有する錠剤の処方例を示す。 処方例 1 錠剤 (配合量：質量 The formulation example of the tablet containing DFAIII is shown. Formulation Example 1 Tablet (Mixed amount: Mass)
DFAIII 77 DFAIII 77
コーンス ーチ 20 Corn Stitch 20
グァーガム 1 Guar gum 1
ステアリン酸マグネシウム 1 実施例 4 Magnesium stearate 1 Example 4
DFAIIIを含有するジュースの処方例を示す。 処方例 2 ジュース (配合量:質量 The formulation example of the juice containing DFAIII is shown. Formulation Example 2 Juice (Amount: Mass)
DFAIII 1 0 DFAIII 1 0
冷凍濃縮温州ミカン果汁 5 Frozen concentrated Wenzhou mandarin orange juice 5
クェン酸 0.2 Cuenic acid 0.2
L-ァスコルビン酸 0.02 L-ascorbic acid 0.02
香料 0.2 Fragrance 0.2
色素 0.1 Dye 0.1
水 84.48
Wed 84.48
Claims
[1] ナトリウム及び Z又はカリウムを排泄促進させる有効成分として、ダイフラクトースァ ンノ、イドライド (DFA)を含有することを特徴とするナトリウム及び Z又はカリウム排泄 促進用経口組成物。 [1] An oral composition for promoting the excretion of sodium and Z or potassium, characterized by containing difractose radionoid, idride (DFA) as an active ingredient for promoting the excretion of sodium and Z or potassium.
[2] ナトリウム及び Z又はカリウム過剰摂取による有害作用を予防、改善する有効成分 として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とするナトリウ ム及び Z又はカリウム過剰摂取予防'改善用経口組成物。 [2] Prevention of excessive intake of sodium and Z or potassium, which is characterized by containing difructose anhydride (DFA) as an active ingredient to prevent and ameliorate adverse effects due to excessive intake of sodium and Z or potassium Composition.
[3] ナトリウム及び Z又はカリウムを排泄促進させる有効成分として、ダイフラクトースァ ンノ、イドライド (DFA)を含有することを特徴とするナトリウム及び Z又はカリウム排泄 促進剤。 [3] A sodium, Z or potassium excretion enhancer characterized by containing difractose radionoid, Ilide (DFA) as an active ingredient for promoting excretion of sodium and Z or potassium.
[4] ナトリウム及び Z又はカリウムを排泄促進させる有効成分として、ダイフラクトースァ ンハイドライド (DFA)を含有することを特徴とする飲食品。 [4] A food and drink characterized by containing difructuan hydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium.
[5] ナトリウム及び Z又はカリウム過剰摂取による有害作用を予防、改善する有効成分 として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とするナトリウ ム及び Z又はカリウム過剰摂取予防 *改善用飲食品。 [5] Prevention of excessive intake of sodium and Z or potassium, characterized by containing difructose anhydride (DFA) as an active ingredient to prevent and ameliorate harmful effects caused by excessive intake of sodium and Z or potassium * Eating and drinking Goods.
[6] ナトリウム及び Z又はカリウムを排泄促進させる有効成分として、ダイフラクトースァ ンハイドライド (DFA)を含有することを特徴とするペット飼料。 [6] A pet feed characterized by containing difructuan hydride (DFA) as an active ingredient that promotes excretion of sodium and Z or potassium.
[7] ナトリウム及び Z又はカリウム過剰摂取による有害作用を予防、改善する有効成分 として、ダイフラクトース アンハイドライド (DFA)を含有することを特徴とするナトリウ ム及び Z又はカリウム過剰摂取予防'改善用ペット飼料。
[7] Prevention of excessive intake of sodium and Z or potassium, which contains difructose anhydride (DFA) as an active ingredient to prevent and ameliorate adverse effects due to excessive intake of sodium and Z or potassium feed.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004-291541 | 2004-10-04 | ||
| JP2004291541A JP4721684B2 (en) | 2004-10-04 | 2004-10-04 | Oral composition containing difructose anhydride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006038613A1 true WO2006038613A1 (en) | 2006-04-13 |
Family
ID=36142686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2005/018346 WO2006038613A1 (en) | 2004-10-04 | 2005-10-04 | Oral composition containing difructose anhydride |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4721684B2 (en) |
| WO (1) | WO2006038613A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081795A1 (en) * | 2006-12-28 | 2008-07-10 | Fancl Corporation | Method for production of dfa iii and plant extract having high dfa iii content |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4880508B2 (en) * | 2007-03-23 | 2012-02-22 | 日本甜菜製糖株式会社 | Immunoglobulin absorption promoting composition |
| JP7137368B2 (en) * | 2017-09-21 | 2022-09-14 | 株式会社ファンケル | Composition for promoting sodium excretion and/or suppressing sodium absorption |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1143438A (en) * | 1997-07-29 | 1999-02-16 | Nippon Beet Sugar Mfg Co Ltd | Calcium absorption-enhancing composition |
| JP2000204042A (en) * | 1999-01-13 | 2000-07-25 | Nippon Mitsubishi Oil Corp | Cyclic oligosaccharide |
| JP2003321371A (en) * | 2002-04-26 | 2003-11-11 | Fancl Corp | Diuretic |
-
2004
- 2004-10-04 JP JP2004291541A patent/JP4721684B2/en active Active
-
2005
- 2005-10-04 WO PCT/JP2005/018346 patent/WO2006038613A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1143438A (en) * | 1997-07-29 | 1999-02-16 | Nippon Beet Sugar Mfg Co Ltd | Calcium absorption-enhancing composition |
| JP2000204042A (en) * | 1999-01-13 | 2000-07-25 | Nippon Mitsubishi Oil Corp | Cyclic oligosaccharide |
| JP2003321371A (en) * | 2002-04-26 | 2003-11-11 | Fancl Corp | Diuretic |
Non-Patent Citations (1)
| Title |
|---|
| HARA HIROSHI.: "Hi Shokasei Torui ni yoru Calcium Kyushu Sokushin Kiko. (Promotive Effects of Nondigestible Saccharides on Calcium Absorbtion)", FOODS & FOOD INGREDIENTS J. JPN., vol. 208, no. 1, 2003, pages 46 - 51, XP002996799 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081795A1 (en) * | 2006-12-28 | 2008-07-10 | Fancl Corporation | Method for production of dfa iii and plant extract having high dfa iii content |
| JP2008162974A (en) * | 2006-12-28 | 2008-07-17 | Fancl Corp | Method for producing dfaiii and dfaiii-rich plant extract |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4721684B2 (en) | 2011-07-13 |
| JP2006104103A (en) | 2006-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3514955B2 (en) | Calcium absorption enhancing composition | |
| JP2011098896A (en) | Composition for reducing uric acid value | |
| JP5788715B2 (en) | Reducing agent for oxygen consumption and energy consumption | |
| WO2006054429A1 (en) | Oral composition containing difructose anhydride | |
| WO2006038613A1 (en) | Oral composition containing difructose anhydride | |
| US20230201255A1 (en) | Composition comprising cinnamaldehyde and zinc to improve swallowing | |
| JP2010111646A (en) | Treating agent for ulcerative colitis | |
| JP4601091B2 (en) | Cyclic oligosaccharide | |
| JPWO2010104175A1 (en) | Oral composition | |
| JP2002193797A (en) | Composition for ameliorating insulin resistance | |
| JPWO2009113594A1 (en) | Functional gastrointestinal disorder preventive / ameliorating agent and food | |
| JP2009526748A (en) | Calcium absorption promoter | |
| JP4460234B2 (en) | Diet food | |
| JP2009209088A (en) | Muscle-enhancing agent containing asperuloside or its analog | |
| JP3248170B2 (en) | Food containing chondroitin sulfate protein complex | |
| JP3345650B2 (en) | Hypertension inhibitor | |
| JP2002255832A (en) | Mineral absorption-promoting agent and anemia- improving agent | |
| JP2004161619A (en) | Osteogenic promoting composition | |
| JP2004149427A (en) | Mineral absorption promoting composition | |
| JPWO2008136173A1 (en) | Adipocyte differentiation inhibitor comprising a stilbene derivative as an active ingredient | |
| JP6434312B2 (en) | Composition, food and drink, visceral fat reducing agent, blood sugar level reducing agent, food and drink for reducing visceral fat, and food and drink for reducing blood sugar level | |
| JP2006001898A (en) | Purine body-adsorbing agent | |
| WO2006080522A1 (en) | Food or drug comprising lactic acid bacterium containing mineral | |
| JP5463011B2 (en) | Nutritional supplement for dialysis patients | |
| JP2007022981A (en) | Reducing agent for ammonia in blood and food and drink reducing ammonia in blood |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05790528 Country of ref document: EP Kind code of ref document: A1 |